Immune Pharmaceuticals Inc (IMNP) Short Interest Up 35.8% in April
Immune Pharmaceuticals Inc (NASDAQ:IMNP) was the recipient of a large growth in short interest in April. As of April 28th, there was short interest totalling 750,273 shares, a growth of 35.8% from the April 13th total of 552,499 shares. Approximately 8.5% of the company’s stock are short sold. Based on an average daily trading volume, of 2,183,226 shares, the days-to-cover ratio is currently 0.3 days.
Shares of Immune Pharmaceuticals (NASDAQ:IMNP) opened at 2.66 on Friday. The company’s market capitalization is $17.46 million. Immune Pharmaceuticals has a 12 month low of $2.14 and a 12 month high of $12.80. The firm’s 50-day moving average is $1.63 and its 200 day moving average is $0.56.
A hedge fund recently raised its stake in Immune Pharmaceuticals stock. Vanguard Group Inc. boosted its position in shares of Immune Pharmaceuticals Inc (NASDAQ:IMNP) by 25.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,983,017 shares of the biopharmaceutical company’s stock after buying an additional 1,001,138 shares during the period. Vanguard Group Inc. owned 75.91% of Immune Pharmaceuticals worth $728,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 2.18% of the company’s stock.
About Immune Pharmaceuticals
Immune Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products.
Receive News & Ratings for Immune Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.